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Introduction: The ergogenic response following long-term ingestion of β-alanine shows
a high inter-individual variation. It is hypothesized that this variation is partially caused by
a variable pharmacokinetic response induced by inferior dosing strategies. At this point
most supplements are either taken in a fixed amount (× g), as is the case with β-alanine,
or relative to body weight (× g per kg BW), but there is currently neither consensus nor
a scientific rationale on why these or other dosing strategies should be used. The aim of
this study is to objectify and understand the variation in plasma pharmacokinetics of a
single oral β-alanine dose supplemented as either a fixed or a weight-relative dose (WRD)
in an anthropometric diverse sample.
Methods: An anthropometric diverse sample ingested a fixed dose (1,400mg) (n = 28)
and a WRD of β-alanine (10 mg/kg BW) (n = 34) on separate occasions. Blood
samples were taken before and at nine time points (up to 4 h) after β-alanine ingestion
in order to establish a pharmacokinetic profile. Incremental area under the curve
(iAUC) was calculated by the trapezoidal rule. Plasma β-alanine was quantified using
HPLC-fluorescence.
Results: The variation coefficient (CV%) of the iAUC was 35.0% following ingestion of
1,400mg β-alanine. Body weight explained 30.1% of the variance and was negatively
correlated to iAUC (r =−0.549; p= 0.003). Interestingly, the CV% did not decrease with
WRD (33.2%) and body weight was positively correlated to iAUC in response to the WRD
(r = 0.488; p = 0.003).
Conclusion: Both dosing strategies evoked an equally high inter-individual variability in
pharmacokinetic plasma profile. Strikingly, while body weight explained a relevant part of
the variation observed following a fixed dose, correction for body weight did not improve
the homogeneity in β-alanine plasma response. We suggest to put more effort into the
optimization of easy applicable and scientifically justified personalized dosing strategies.
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INTRODUCTION
In sports nutrition, there is no uniformity in dosing strategies of ergogenic supplements to adults.
A fixed dose (FD; × g per person per day) is by far the easiest to implement in daily practice
and allows straightforward packaging and marketing. On the other hand, dosing is sometimes
normalized for anthropometric characteristics. The weight-relative dose (WRD; × g per kg body
weight per day), which is by far the most popular normalizing strategy, is somewhat less practical
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to prescribe but may seem more adequate. The WRD is expected
to correct for differences in body size and weight, which can
easily differ by a factor 3 between, say, a female gymnast and
a male American Football lineman. There is a striking paucity
in the nutrition literature in general and in the sports nutrition
literature in particular, relating to the pros and cons of these
two, or any other normalization approach and even more so
relating to the physiological differences and direct comparison of
different approaches.
β-alanine (BA) is classified as a Group A supplement in the
Sport Supplement Program of the Australian Institute of Sport1
as it has been shown to improve performance of exercises lasting
between 0.5 and 10min (1). Its ergogenic effect is achieved by
the intra-muscular increase of the dipeptide carnosine that is
constituted from histidine and its rate-limiting precursor BA.
Carnosine has multiple biochemical properties whereof its ability
to buffer protons most likely is the major determinant that
explains its ergogenic potential (2).
Currently, a FD is the most popular strategy in BA
supplementation although different absolute doses are used (1).
In the first report of BA as a human food supplement, Harris
et al. investigated the pharmacokinetics of three different BA
doses supplemented as WRD (10, 20, and 40 mg/kg BW) (3).
Subsequently, these authors switched to FD and investigated the
effect of a 15-d supplementation protocol of 3.2 and 6.4 g/d
(FD) on muscle carnosine. In follow-up, Hill et al. (4) performed
the first study on BA as an ergogenic food supplement with a
FD (4–6.4 g/day). Thereafter (almost) all research, by this and
other groups, was performed with absolute dosing strategies, but
without further rationale.
As in many other supplementation studies, the improvement
in exercise performance following BA ingestion is characterized
by a lot of variation. For example, Saunders et al. (5) found
that performance changes ranged from +0.0 to +72.7% (CV%
> 60%) in distance covered in a YoYo intermittent recovery test
level 2 (5). This is not surprising, as many others have shown that
the variation inmuscle carnosine loading is quite high as well. For
example, Blancquaert et al. (6) found a change of gastrocnemius
carnosine from 3.3% up to 119.0% (CV% = 74%) in people
receiving 6.4 g BA for 23 days (6). As Hill et al. (4) showed that
the change in muscle carnosine explains part of the change in
performance, we can hypothesize that by reducing the variation
in muscle carnosine increments, the ergogenic effect might also
be more uniform. Interestingly, the coefficient of variation in
BA’s pharmacokinetic response was reported to be 32% in a
standardized setting (7). As it was shown that muscle carnosine
loading was correlated to plasma BA concentration in mice (8)
and to fasted plasma BA concentrations after a supplementation
period in humans [unpublished, data of Blancquaert et al. (6)], it
is very likely that the variation in carnosine loading and therefore
ergogenic response is explained, in part, by the variation in the
acute pharmacokinetic profile of BA.
1Australian Sports Commission Group A sports supplement AIS. Available online
at: https://www.ausport.gov.au/ais/nutrition/supplements/groupa (Accessed
March 20, 2018).
As it is the objective of any sport supplement to optimize
performance, it is obvious that athletes require correct and
perhaps personalized dosing that induces a homogenous
pharmacokinetic and ergogenic response. Providing a
subtherapeutic dose might fail to affect performance, whereas
supratherapeutic dosing might decrease performance or could
even cause (unhealthy) side effects. In case of BA, low ingestion
leads to the lack or low increases of carnosine, most likely
insufficient to affect performance (4, 9). On the other hand,
a supratherapeutic dose of BA can acutely cause discomfort
in the form of paraesthesia (3). Due to the acute side-effects
of BA, a slow release formula was developed in order to
reduce peak concentration but maintain total pharmacokinetic
response (AUC) (7). Some have also suggested that chronic
ingestion of high doses of BA can cause a decline in muscle and
plasma histidine (6, 10), whereby a negative effect on health or
performance cannot be excluded. On the other hand, others did
not observe a decline in muscle histidine following chronic BA
supplementation (3, 11). In general, one could expect that with a
FD the smaller/lighter people will be more prone to overdosing
and the larger/heavier people to underdosing. However, it might
equally be that with WRD the reverse is occurring (smaller
people get underdosed and larger people overdosed). The latter
was suggested for carbohydrate ingestion and bioavailability
during exercise since it was argued that this is more dependent
on GI tract characteristics rather than on body weight thereby
pleading in favor of a FD for carbohydrates (12).
Summarized, there is at this point no scientific rationale to
use a FD in BA supplementation. On the other hand, there
is no information why other dosing strategies should be used.
Based on the current knowledge there is no way to know which
dosing strategy evokes the most homogenous plasma response.
Therefore, the aim of this study is to objectify and to understand
the variation in plasma pharmacokinetics of a single oral BA dose
(FD or WRD) in an anthropometric diverse sample.
METHODS
Subjects
Thirty-four subjects (age 25.1 ± 4.29 y; body weight: 70.4 ±
14.9 kg; height: 1.73 ± 0.11m); volunteered to participate in the
first part of this study (WRD) whereof 28 (age: 24.8 ± 4.25 y;
body weight: 68.1± 15.2 kg; height: 1.72± 0.11m) completed the
second part (FD) (Table 1). All subjects were in good health and
none of the participants was vegetarian. Both males and females
(WRD: 19 males/15 females and FD: 14 males/females) from
a mixed ethnic background were recruited. The study protocol
was approved by the local ethical committee (Ghent University
Hospital, Belgium) and written informed consent was obtained
from all participants before the study.
Study Design and Sample Collection
Subjects arrived fasted at the lab at two separate occasions.
At arrival, a catheter was inserted in an antecubital vein and
the first blood sample was taken (heparin tube). Hereafter, a
standardized breakfast, consisting of white bread, hazelnut paste
(Nutella) and semi skimmed milk, was consumed. The total
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TABLE 1 | Anthropometric characteristics sample.
FD (1,400mg) WRD (10mg kg−1)
N Men 14 19
Women 14 15
Age (year) Min 18 18
Max 34 35
Mean 24.8 25.1
SD 4.3 4.3
Body weight (kg) Min 46.0 46.0
Max 104.5 104.5
Mean 68.1 70.4
SD 15.2 14.9
Height (m) Min 1.50 1.50
Max 1.94 1.94
Mean 1.72 1.73
SD 0.11 0.11
FD, fixed dose; WRD, weight-relative dose.
calorie count of the breakfast was 23% (388 ± 50 kcal) of the
resting metabolic rate (RMR) as calculated by the formula of
Miﬄin (13) (1,672± 204 kcal). Ten minutes after the start of the
breakfast, a single dose of pure BA (Indis nv, Belgium) in gelules
was ingested with water. Consecutively nine blood samples were
taken after 20, 40, 60, 90, 120, 150, 180, 210, and 240min.
During the experiment, subjects drank water ad libitum and they
refrained from any physical activity. All participants received a
relative dose of 10 mg/kg body weight pure BA on the first test
day, whereas 28 of the 34 participants returned for a second
experimental test day where they received an absolute dose of
1,400mg. To obtain information about the subjective feelings and
the location of paraesthesia, the subjects received a standardized
questionnaire at the end of every experimental day asking for
the occurrence, intensity, localization, timing and description of
possible discomfort/side-effects (7).
The absolute dose of 1,400mg corresponded to a relative dose
of 20.79 ± 4.45 mg/kg BW (range: 13.40–30.43 mg/kg BW),
whereas the relative dose matched 703.5± 149.4mg (range: 460–
1,045mg). Standardized allocation of experimental test days was
used in order to test for potential paraesthesia occurring with
the lower dose (WRD), before exposing subjects to a higher dose
(FD).
Determination of Plasma Metabolites by
High-Performance Liquid Chromatography
Heparin plasma samples were analyzed for BA using a previously
published HPLC method (6). In short, heparin plasma samples
were deproteinized using a 1:9 ratio of 35% sulfosalicylic acid.
Plasma supernatant was mixed with ACCQ Fluor Borate buffer
and Fluor reagent from the AccQtag Chemistry kit (Waters
sa-nv, Belgium) in a 1:7:2 ratio. Standard solutions of BA
were treated similarly before HPLC analyses. The derivatized
samples were applied to a Waters Alliance HPLC system
with the following parameters: XBridge BEH column (4.6 ×
150mm, 2.5µm; Waters) heated to 37◦C; fluorescence detector
(excitation/emission wavelength: 250/395 nm); using a flow
gradient containing different amounts of buffer A (10% eluent A
[Waters], 90% ddH2O), buffer B (100% acetonitrile), and buffer
C (100% ddH2O) at a flow rate of 1mL.min−1.
Pharmacokinetics and Statistical Analysis
Pharmacokinetics was investigated using a first order kinetic
and non-compartmental model. Incremental area under the
curve (iAUC) was calculated by subtracting the baseline of
the AUC calculated using the trapezoidal rule. Cmax was
determined as the maximal concentration measured, whereas
Tm was determined as the time Cmax was reached. T1/2 was
calculated as 0.693 divided by the elimination constant (ke),
whereas the ke was computed as −2.303 multiplied by the
slope of the individual linear curve of the log10 from Cmax
till the concentration at time 240min (14). CV% (standard
deviation divided bymean) was calculated for all variables. Before
statistical analysis, normality of the continuous variables was
checked using Shapiro-Wilk. Multivariate analyses of variance
(MANOVA) was performed to determine the role of sex on
the different pharmacokinetic parameters following FD. Pearson
correlations and linear regression were performed between the
anthropometric and pharmacokinetic parameters. All statistical
analyses were performed using the Statistical Package for the
Social Sciences (version 25.0; SPSS, Chicago, IL). Values are
presented as mean ± SD and significance was assumed at P ≤
0.05.
RESULTS
Variability With FD
The inter-individual variability in iAUC and Cmax that could be
observed in BA plasma pharmacokinetics following ingestion of
a single FD of 1,400mg BA was 35.0% (18,550 ± 6,495µM.min;
range: 9,334–38,183) and 40.2% (218.4 ± 87.9µM; range: 91.7–
440.5), respectively (Figure 1A) (Table 2). The T1/2 varied from
32.6 to 97.8min and Tm varied from 40 to 150min. These
pharmacokinetic parameters were not significantly different
between sexes (data not shown).
Anthropometric Factors Underlying the
Variation With FD
The iAUC of the FD was negatively correlated with body weight,
height and RMR, but not to BMI (Figure 2). The strongest
correlation with plasma iAUC was found for height, explaining
33.8% of the variance, which was only slightly higher than the
30.1% explained by body weight (Table 3). Cmax of FD was also
correlated to all anthropometrics (Table 3). Body weight had the
highest explained variance (29.1%) for Cmax.
Variability With WRD
We also investigated the pharmacokinetic response following
ingestion of 10 mg/kg BW BA (WRD). Despite this body weight
correction of dosing, a nearly equally high inter-individual
variability was observed (Table 2; Figure 1B) and the fold-
difference between the highest and lowest responder was even
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FIGURE 1 | Variability in plasma pharmacokinetics in an anthropometric diverse sample following a (A) fixed (FD) and (B) weight-relative dose (WRD). Plasma
β-alanine (BA) concentrations (µM) were determined before and at nine time points after the ingestion of 1,400mg (A) or 10 mg/kg BW (B) BA. The observed variation
in iAUC is 35.0 and 33.2%, respectively.
TABLE 2 | Observed variation in iAUC and Cmax in both dosing strategies.
FD WRD
iAUC %CV 35.0 33.2
Fold difference (highest vs. lowest) 4.09 7.16
Cmax %CV 40.2 37.5
Fold difference (highest vs. lowest) 4.81 6.25
FD, fixed dose; WRD, weight-relative dose.
more pronounced. The CV% of iAUC and Cmax was 33.2%
(6,134± 2,038µM.min; range: 1,424–10,201) and 37.5% (69.0±
25.9µM; 19.6–122.2µM), respectively.
The iAUC of the WRD was positively correlated to body
weight, height, BMI, and RMR (Figure 3), while Cmax was
correlated to body weight and RMR but not to height and BMI
(Table 3).
Relationship Dose and iAUC
As the FD and WRD were in a different absolute dose range, we
investigated the link between dose and iAUC. There was a non-
linear relationship between the dose and the iAUC on both the
individual and the population level (Figure 4).
Side Effects
Nobody reported paraesthesia following WRD and two subjects
reported paraesthesia following ingestion of FD. These subjects
did not have the highest values of AUC, Cmax, Tm, or T1/2 of the
evaluated population, but the moment of paraesthesia matched
their individual Cmax value.
DISCUSSION
In this study, the inter-individual differences in pharmacokinetic
response (iAUC) following BA ingestion are described. The
iAUC is a crucial parameter because it reflects the concentration
and duration of elevated plasma BA. It is assumed that the
variation in acute BA pharmacokinetic profile reflects the variable
response on carnosine loading and thereby ergogenic outcome
following long-term BA supplementation. The coefficient of
variation of the iAUC was 35.0% following a FD (Figure 1A),
with a marked 4-fold difference between the lowest and highest
iAUC. This variation resembles the 32% variation reported by
Décombaz et al. (7). Seeking for an explanation for the high
diversity in physiological response, it was observed that body
weight explained a relevant part (30.1%) of the variability in
plasma kinetic response. The negative correlation to body weight
(r = −0.549; p = 0.003) signifies that heavy people received
too little and light people received too much BA, to cause a
homogenous response. The current observations call for a body
weight correction to personalize dosing.
The striking observation of the current study is that the body
weight correction (10 mg/kg BW) did not improve homogeneity
in BA plasma response, with a CV% of 33.2% and an even more
pronounced 7-fold difference between lowest and highest iAUC
(Figure 1B). Instead of a negative correlation, there was now a
positive correlation with body weight (r =0.488; p= 0.003). This
means that when trying to correct the dose for body weight, the
problem is reversed, thereby overdosing the heavy people and
underdosing the less heavy people. Thus, although the principle
of weight-corrected dosing seemed valid for BA, we simply
replaced one problem by an equally large new problem, leading
to zero progression toward homogeneity and individualized
supplementation.
One possible explanation for the failure to improve
homogeneity of supplement response could be that body weight
is not the optimal scaling factor for dose calculation. Other
body dimensions might more accurately reflect determinants
of the pharmacokinetic response through for example GI tract
dimension and therefore absorption surface, liver volume and
thereby BA degradation capacity (8), kidney volume (15), blood
volume (16), etc. However, other parameters, such as height,
BMI, or RMR (Figure 2; Table 2) did not yield a better explained
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FIGURE 2 | A negative correlation is observed between iAUC of the fixed dose and the anthropometric characteristics: body weight (BW) (A), height (B), resting
metabolic rate (RMR) (C), and BMI (D).
TABLE 3 | Correlations between anthropometrics vs. iAUC and Cmax.
FD WRD
iAUC Cmax iAUC Cmax
BW r −0.549* −0.540* 0.488* 0.360*
r2 0.301 0.291 0.238 0.130
Height r −0.581* −0.531* 0.415* 0.313$
r2 0.338 0.282 0.172 0.098
BMI r −0.339$ −0.378* 0.401* 0.289$
r2 0.115 0.143 0.161 0.083
RMR r −0.535* −0.522* 0.479* 0.364*
r2 0.287 0.273 0.230 0.132
FD, fixed dose; WRD, weight-relative dose *p < 0.05; $0.05 < p < 0.10.
variance than body weight in the current study. Therefore, we
believe that, when scaling is appropriate, body weight might still
partially be a relevant scaling factor, as it is the easiest to translate
and adopt to the population.
Since both the pharmacokinetic response of the FD and
WRD suffered equally from an influence of body weight, yet
in opposite directions, we now propose that supplement dosing
should only partially be scaled to body weight. One approach
would be to consider 50% of the dose to be given as a FD and
50% as a WRD, with a 70 kg person as a reference. Transferred
to the example of a targeted 1,400mg or 20 mg/kg BW BA,
a 70 kg person would receive 700mg as FD and 700mg as 10
mg/kg body weight. Thus, with this scheme (700mg as FD
and 10 mg/kg BW as WRD), this would result in a 1,200mg
dose for a 50 kg person and 1,700mg for a 100 kg person.
An alternative approach would be to normalize the entire
dose to only a portion of the body weight. When comparing
anthropometrically diverse populations, scaling maximal oxygen
uptake to body weight is usually done by dividing VO2 by 2/3rd
of the lean body mass (17). The latter is less likely to be easily
adoptable because it requires lean body mass determination and
calculation beyond the general public’s abilities. It is important
to consider that, the dose-scaling strategies presented here can
only be used as a suggestion since these were not tested in this
study.
Another interesting observation was that the iAUC was non-
lineary related to the dose (Figure 4). This implies that especially
with higher dosage, a certain change of dose will not induce the
same effect on the iAUC. In the former example this means that
when a 100 kg person ingests a WRD of 20 mg/kg BW (2,000mg)
or a partially FD and WRD of 700 + 10 mg/kg BW (1,700mg)
this would result in a 87 and 40% increase of iAUC while the
dose only increased 43 and 21%, respectively, compared to a FD
of 1,400mg. The fact that the dose is non-linearly related to iAUC
adds an extra layer of complexity in future research investigating
different dosing strategies.
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FIGURE 3 | A positive correlation is found between the iAUC of the weight-relative dose and the anthropometric characteristics: body weight (BW) (A), height (B),
resting metabolic rate (RMR) (C), and BMI (D).
FIGURE 4 | The iAUC of β-alanine is non-linearly related with the
supplemented dose. The mean is shown in black, whereas the individual
values are shown in gray.
In the current experiment, a quite diverse sample was included
consisting of men and women, from different ethnicities and with
different anthropometric characteristics. The current sample
somewhat resembles the population toward which results should
be generalized, although our sample did not include people above
105 kg and 1m94, which is a limitation. Current standard practice
is to supplement athletes with a fixed dose. In this sample, the
fixed dose of 1,400mg resembled a relative dose of 13 and 30
mg/kg BW for the heaviest and lightest subjects respectively. A
WRD of 30 mg/kg BW is already quite high when considering
the pioneering study reported significant side-effects, although
not recorded as unpleasant, at a dose of 20 mg/kg BW (3). On
the other hand, including more heavy subjects would most likely
have resulted in an even smaller physiological response when
ingesting the fixed dose (<13 mg/kg BW). In future research, it
is the scientific community’s responsibility to test and formulate
recommendations for all athletes, also those with more extreme
anthropometric characteristics.
Although other supplements are characterized by a different
metabolism, similar dose related considerations have not yet been
made for the other evidence-based performance supplements.
Within each supplement there exists a more or less standard
practice, with bicarbonate and caffeine being administered in
WRD and creatine and nitrate mostly used in FD. Interestingly,
it seems that the adopted dosing strategy is primarily based
on the pioneering study. Jones et al. (18) were the first to
investigate bicarbonate as an ergogenic supplement and used a
WRD (0.3 g/kg), whereafter the community continued to do so.
Creatine and nitrate are mostly used in FD in accordance with
the pioneers who supplemented a FD of 5 g/dose, 4–6 times a
day (3), and 500 ml/day beetroot juice (NO3−:5.5 mmol/day)
(19) to improve exercise, respectively. In contrast, pioneering
researchers used caffeine in a FD of 330mg (20), but the scientific
community shifted toward the use of WRD. One might suggest
that, at this point, WRD is mostly used in ergogenic aids that
are taken acutely and whereby overdosing might cause ergolytic
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effects. In contrast, convenient FD is used when supplements
are chronically administered and when acute side effects are not
likely to affect performance. In any case, there is at this point no
scientific justification on why current dosing strategies are used
in relation to optimization of personalized responses.
In the present study, a FD and WRD of 1,400mg and
10 mg/kg BW were used, respectively. The FD of 1,400mg
corresponded to a relative dose of 13.40–30.43 mg/kg BW,
whereas the WRD matched 460mg up to 1,045mg. These
doses and the corresponding physiological response (iAUC)
are different, making direct comparison between two dosing
strategies used in this investigation impossible. We acknowledge
this difference in absolute dose between de FD and WRD
conditions as a limitation to the current study. Nonetheless, we
deem the conclusions of the current data as valid and valuable.
In summary, the current study showed that—at least for
the example of BA—neither FD nor WRD is adequate toward
personalized nutrition, since in both cases the observed variation
was equally high and partially explained and correlated to
anthropometrics. This underscores the importance to better
address the relationship between different doses of nutritional
supplements and the physiological responses they elicit in an
anthropometric diverse sample. Future studies will need to test
more advanced dose-scaling strategies, where after it will be
possible to provide scientifically based recommendations for
provokingmore homogenous physiological responses in athletes.
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